G20 Declaration on Combatting Antimicrobial Resistance (AMR) 7-8th July 2017

Destiny Pharma welcomes the G20 Leaders´ Declaration on Combatting Antimicrobial Resistance (AMR) following their meeting in Germany. The G20 Leaders highlighted:

  1. The importance of fostering Research & Development, particularly for priority pathogens as identified by the WHO
  2. Called for the establishment of a new international Research & Development Collaboration Hub to maximise the impact of existing and new anti-microbial basic and clinical research initiatives, as well as product development
  3. Invited all interested countries and partners to join this new initiative
  4. The G20 Leaders will also, in collaboration with relevant experts including from the OECD and the WHO, further examine practical market incentive options

The full G20 Leaders’ Declaration can be found here.

To the G20: Incentivise Antibacterial Drug R&D

Andrew Jack of the Financial Times today reports that Angela Merkel, (German chancellor & G20 President), has put health at the centre of today and tomorrow’s meeting of leading nations in Hamburg. High on their agenda will be attempts to tackle Infectious Diseases that present a growing health, economic and security threat across borders. The G20 meeting will look at how to respond to pandemics and there will also be a specific emphasis on one significant threat that is well understood but still neglected: ‘Anti Microbial Resistance (AMR)’.

Yesterday, DRIVE-AB, a joint undertaking between the EU and the European Pharmaceutical Industry Association) commented on their findings that are pertinent to G20 commitments, calling for the following incentives to drive forward antibacterial drug R&D to combat AMR:

  • Pay between $750 million and $2 billion Market Entry Rewards to companies introducing new antibacterial drugs
  • Global banking institutions to offer novel financial instruments to further support antibacterial R&D
  • Top up currently available AMR ‘Push’ funding by $250 million pa
  • Develop health technology assessment reimbursement rules which recognise the societal value of antibiotics
  • Establish multinational coordination and collaboration

The speed and frequency of emergence of new Superbugs was underlined by the World Health Organization today after reporting on the discovery of totally untreatable Superbug strains of gonorrhoea and warning of their potential spread. Two studies on gonorrhoea published in the journal PLOS Medicine documented cases in Japan, France and Spain of patients with strains of gonorrhoea against which no known antibiotic is effective. The WHO estimates 78 million people a year get gonorrhoea.

Regulators from EU, U.S. and Japan join forces on antimicrobial trials

Destiny Pharma is pleased to note that the European Medicines Agency (EMA), the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) and the United States’ Food and Drug Administration (FDA) have agreed to align their data requirements for antimicrobial trials, aimed at stimulating the development of new treatments to fight antimicrobial resistance. More information is available on the EMA website.

Destiny Pharma in attendance at the 18th Bio€quity Europe Meeting, Paris, France

Neil Clark, CEO of Destiny Pharma will be attending the Bio€quity Europe 2017 meeting, to be held between the 22-23rd May in Paris, France and will be presenting information about the company on the morning of Tuesday the 23rd May. If you are attending the conference and would like to book an appointment to meet with Neil, please email us on conferences@destinypharma.com.

Destiny Board Member Elected to the Academy of Medical Sciences

Brighton, United Kingdom – 9th May, 2017 – Destiny Pharma, a clinical stage biotech company focused on the development of new anti-microbial drugs, is pleased to announce that one of its Board members, Professor David Roblin, has been elected to the Academy of Medical Sciences. David has been a director of Destiny Pharma since 2011 and the Board of Destiny congratulates him on this prestigious award.

David has recently been appointed Chief Operating Officer and President of R&D of Summit Therapeutics. Prior to this, he was Chief Operating Officer and Director of Scientific Translation at the Sir Francis Crick Institute. He was also formerly Senior Vice President and Head of R&D for Pfizer’s European sites, as well as Head of Therapy Area for Anti-Infectives at Bayer. David has a first degree in biochemistry from University College London and later qualified in medicine from St George’s Hospital.

Previous recipients include Professor Françoise Barré-Sinoussi, director of Unité de Régulation des Infections Rétrovirales, Chen Zhu, China’s Minister of Health, and Sir Andrew Witty, the former Chief Executive Officer of GlaxoSmithKline.

For full details of the announcement please visit: https://www.crick.ac.uk/news/news-archive/2017/05/08/david-roblin-and-robert-wilkinson-elected-to-the-academy-of-medical-sciences/

For further information, please visit www.destinypharma.com or contact:  

Destiny Pharma Ltd

pressoffice@destinypharma.com

FTI Consulting

Simon Conway / Victoria Foster Mitchell / Hanna Skeppner

destinypharma@fticonsulting.com

+44 (0) 2037 271000

Notes for Editors

About the Academy of Medical Sciences

The Academy of Medical Sciences is the independent body in the UK representing the diversity of medical science. Our elected Fellows are the UK’s leading medical scientists from hospitals, academia, industry and the public service. Our mission is to advance biomedical and health research and its translation into benefits for society. We are working to secure a future in which:

  • UK and global health is improved by the best research.
  • The UK leads the world in biomedical and health research, and is renowned for the quality of its research outputs, talent and collaborations.
  • Independent, high quality medical science advice informs the decisions that affect society.
  • More people have a say in the future of health and research.

Our work focusses on four key objectives, promoting excellence, developing talented researchers, influencing research and policy and engaging patients, the public and professionals.

www.acmedsci.ac.uk

About Destiny Pharma Ltd

Destiny Pharma is a clinical stage biotechnology company focused on the development of novel anti-infective drugs to combat antibiotic-resistant bacteria, addressing a growing global unmet clinical need. Destiny’s patented XF drug platform represents a new approach to treat infectious disease, based on a novel molecular structure and a unique mechanism of action. XF drugs, unlike conventional antibiotics, are able to kill bacteria in any growth phase ultra-rapidly, with lower potential for the emergence of drug resistance.

The Company has completed five successful Phase I/IIa clinical trials with its lead drug, XF-73 (exeporfinium chloride). XF-73 has been awarded Qualifying Infectious Disease Product (QIDP) status and is being initially developed for the prevention of post-surgical staphylococcal infections, a potentially blockbuster indication of high unmet medical need. Destiny’s XF drug platform is being developed to prevent and treat existing and emerging “superbug” infections with a broad range of application in both primary and secondary healthcare settings.

Destiny Pharma announces appointment of new CEO

Destiny Pharma announces appointment of new CEO

 Neil Clark brings extensive leadership experience in clinical stage biopharmaceutical companies, as the Company plans Phase IIb trial for lead asset in potentially blockbuster indication

 Dr Bill Love, Destiny’s founder, to become Chief Scientific Officer

 

Brighton, United Kingdom – 13 April, 2017 – Destiny Pharma, a clinical stage biotech company focused on the development of new anti-microbial drugs, is pleased to announce the appointment of Neil Clark as Chief Executive Officer (CEO) and member of the Board of Directors, effective immediately. Concurrently, Destiny’s scientific founder and previous CEO, Dr Bill Love, has been appointed to Chief Scientific Officer (CSO).

Sir Nigel Rudd, Non-Executive Chairman of Destiny Pharma, commented:

I am delighted to welcome Neil Clark as Chief Executive Officer of the Company. Destiny has made significant progress in the last two years, concluding in 2016 with very encouraging results from a National Institute of Health-sponsored proof-of-concept clinical study with XF-73, the lead drug from our XF drug platform. As we move forward, Neil’s extensive leadership experience in clinical stage biopharmaceutical companies will be invaluable as Destiny starts planning its first Phase IIb clinical trial. In this trial, the Company will be investigating XF-73 as a potential first-in-class drug for the prevention of post-surgical infections from all strains of Staphylococcus aureus, which we believe is a blockbuster opportunity.

“Bill Love, the founder of the Company, will continue his scientific leadership of Destiny in the newly created role of Chief Scientific Officer. As a recognised thought leader in combating the global issue of anti-microbial resistance, he will continue to focus on developing the XF platform and earlier stage projects, as the Company seeks to expand and further strengthen its already robust intellectual property position.”

On his appointment, Mr Clark added:

I am delighted to be joining the team at Destiny at an exciting time. The resistance to antibiotics is becoming a global issue that needs to be addressed and I believe Destiny has a significant part to play. The Company has a clear focus on developing effective anti-infective drugs with low/no resistance profiles and has a potentially valuable lead asset ready to enter Phase IIb clinical development.

Neil Clark joins Destiny from Ergomed plc, a company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs. Neil Clark joined Ergomed as Chief Financial Officer (CFO) in January 2009 and was CFO at its initial public offering in July 2014 until his move to be full time CEO of Ergomed’s PrimeVigilance business in January 2016. Prior to Ergomed, he was at CeNeS Pharmaceuticals plc, a company focused on developing drugs for central nervous system disorders and pain control, as CFO and subsequently CEO until its sale in 2008. Neil has spent 20 years in private and public life science companies and has a range of international experience in drug research and development, as well as licensing and partnering. 

For further information, please visit www.destinypharma.com or contact:

Destiny Pharma Ltd

pressoffice@destinypharma.com

FTI Consulting

Simon Conway / Victoria Foster Mitchell / Hanna Skeppner

destinypharma@fticonsulting.com

+44 (0) 2037 271000

About Destiny Pharma Ltd

Destiny Pharma is a clinical stage biotechnology company focused on the development of novel anti-infective drugs to combat antibiotic-resistant bacteria, addressing a growing global unmet clinical need. Destiny’s patented XF drug platform represents a new approach to treat infectious disease, based on a novel molecular structure and a unique mechanism of action. XF drugs, unlike conventional antibiotics, are able to kill bacteria in any growth phase ultra-rapidly, with lower potential for the emergence of drug resistance.

The Company has completed five successful Phase I/IIa clinical trials with its lead drug, XF-73 (exeporfinium chloride). XF-73 has been awarded Qualifying Infectious Disease Product (QIDP) status and is being initially developed for the prevention of post-surgical staphylococcal infections, a potentially blockbuster indication of high unmet medical need. Destiny’s XF drug platform is being developed to prevent and treat existing and emerging “superbug” infections with a broad range of application in both primary and secondary healthcare settings.

Destiny Pharma to attend the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Vienna, Austria

Destiny Pharma will be attending the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), which will take place in Vienna, Austria, from 22 – 25 April 2017. Please contact us on conferences@destinypharma.com if you would like to arrange a meeting during the ECCMID meeting.

Destiny Pharma to present at the 18th BioEquity Europe Meeting, Paris, France

Destiny Pharma today announced that they will be presenting at the BioEquity Europe 2017 meeting, to be held between the 22-23rd May in Paris, France. If you are attending the conference and would like to book an appointment to meet with us, please email us on busdev@destinypharma.com.

 

For more information on the meeting, please visit the BioEquity Europe page